• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    6/3/24 12:31:06 PM ET
    $BPTH
    $CCM
    $CNSP
    $CRBU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $BPTH alert in real time by email

    Gainers

    • Structure Therapeutics (NASDAQ:GPCR) stock moved upwards by 71.0% to $58.47 during Monday's regular session. The market value of their outstanding shares is at $2.7 billion.
    • Concord Medical Services (NYSE:CCM) stock rose 55.96% to $0.78. The company's market cap stands at $33.8 million.
    • Microbot Medical (NASDAQ:MBOT) shares moved upwards by 40.79% to $1.41. The market value of their outstanding shares is at $20.2 million.
    • Bio-Path Hldgs (NASDAQ:BPTH) shares moved upwards by 38.0% to $2.84. The market value of their outstanding shares is at $4.7 million.
    • Olema Pharmaceuticals (NASDAQ:OLMA) shares rose 23.45% to $11.95. The market value of their outstanding shares is at $668.4 million.
    • Eterna Therapeutics (NASDAQ:ERNA) shares rose 22.1% to $2.32. The company's market cap stands at $12.5 million.

    Losers

    • CNS Pharma (NASDAQ:CNSP) shares decreased by 32.2% to $0.15 during Monday's regular session. The company's market cap stands at $1.7 million.
    • Galera Therapeutics (NASDAQ:GRTX) shares fell 31.67% to $0.15. The company's market cap stands at $7.9 million.
    • Portage Biotech (NASDAQ:PRTG) shares decreased by 26.92% to $0.35. The market value of their outstanding shares is at $6.9 million.
    • Caribou Biosciences (NASDAQ:CRBU) shares fell 25.0% to $2.16. The market value of their outstanding shares is at $195.0 million.
    • iSpecimen (NASDAQ:ISPC) shares decreased by 23.13% to $0.33. The company's market cap stands at $3.2 million.
    • Werewolf Therapeutics (NASDAQ:HOWL) stock fell 22.25% to $4.02. The market value of their outstanding shares is at $174.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BPTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BPTH
    $CCM
    $CNSP
    $CRBU

    CompanyDatePrice TargetRatingAnalyst
    Olema Pharmaceuticals Inc.
    $OLMA
    2/11/2026$48.00Buy
    Stifel
    Microbot Medical Inc.
    $MBOT
    2/10/2026$5.00Buy
    B. Riley Securities
    Olema Pharmaceuticals Inc.
    $OLMA
    1/7/2026$40.00Overweight
    Piper Sandler
    Werewolf Therapeutics Inc.
    $HOWL
    12/19/2025$1.00Outperform → Neutral
    Wedbush
    Microbot Medical Inc.
    $MBOT
    12/3/2025$5.50Buy
    Roth Capital
    Olema Pharmaceuticals Inc.
    $OLMA
    10/8/2025$20.00Buy
    Guggenheim
    Olema Pharmaceuticals Inc.
    $OLMA
    8/12/2025$20.00 → $21.00Buy
    Citigroup
    Structure Therapeutics Inc.
    $GPCR
    5/2/2025$60.00Buy
    Citigroup
    More analyst ratings

    $BPTH
    $CCM
    $CNSP
    $CRBU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time

    HINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will be participating at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16-19, 2026. This marks the first time the Company has been invited to participate in this conference, reflecting growing market interest in the Company. Harel Gadot, CEO, President & Chairman will present live at 8:40 am ET on Thursday, March 19th. Mr. Gadot will highlight recent achievements from LIBERTY's limited market release and review key market growth drivers that the Company believes

    3/10/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights. "2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs," said Rachel Haurwitz, PhD, Caribou's president and CEO. "The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this program is delivering on the prom

    3/5/26 4:05:00 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation

    HINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, commends the American Medical Association's (AMA) expanding efforts to protect health care professionals from ionizing radiation. In late 2025, the AMA adopted a new policy to strengthen protections for health care professionals and trainees who may face occupational radiation exposure. The policy emphasizes the importance of continued research into the health effects of cumulative exposure to ionizing radiation, the effectiveness of Personal Protection Equipment (PPE), and education and training to minimize occupational r

    3/4/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BPTH
    $CCM
    $CNSP
    $CRBU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Olema Pharmaceuticals with a new price target

    Stifel initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $48.00

    2/11/26 7:52:37 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Microbot Medical with a new price target

    B. Riley Securities initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.00

    2/10/26 8:01:31 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Olema Pharmaceuticals with a new price target

    Piper Sandler initiated coverage of Olema Pharmaceuticals with a rating of Overweight and set a new price target of $40.00

    1/7/26 9:13:12 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    $CCM
    $CNSP
    $CRBU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF LEGAL OFFICER Mitchell Shawnte exercised 40,000 shares at a strike of $4.37, sold $945,750 worth of shares (39,767 units at $23.78) and sold $5,753 worth of Comon Stock (233 units at $24.69) (SEC Form 4)

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    3/5/26 8:00:07 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF TECHNOLOGY OFFICER Ma Yingli covered exercise/tax liability with 11,313 units of Ordinary Shares, decreasing direct ownership by 10% to 107,391 units (SEC Form 4)

    4 - Structure Therapeutics Inc. (0001888886) (Issuer)

    3/5/26 6:20:13 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Coll Crespo Blas covered exercise/tax liability with 11,826 units of Ordinary Shares, decreasing direct ownership by 5% to 204,981 units (SEC Form 4)

    4 - Structure Therapeutics Inc. (0001888886) (Issuer)

    3/5/26 6:20:16 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    $CCM
    $CNSP
    $CRBU
    SEC Filings

    View All

    $BPTH
    $CCM
    $CNSP
    $CRBU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 144 filed by Olema Pharmaceuticals Inc.

    144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    3/11/26 4:20:04 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CNS Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    3/11/26 8:35:29 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Olema Pharmaceuticals Inc.

    144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    3/10/26 12:27:57 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Cherington Charles bought $2,000,000 worth of shares (4,000,000 units at $0.50), increasing direct ownership by 144% to 6,779,440 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    2/17/26 9:14:34 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Cherington Charles bought $2,221,826 worth of shares (21,241,163 units at $0.10), increasing direct ownership by 104% to 41,659,743 units (SEC Form 4)

    4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

    6/11/25 8:34:12 PM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $487,188 worth of shares (536,426 units at $0.91) (SEC Form 4)

    4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)

    5/14/25 6:08:19 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    $CCM
    $CNSP
    $CRBU
    Leadership Updates

    Live Leadership Updates

    View All

    Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG

    CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of Dr. Ira S. Winer, M.D., Ph.D., FACOG, to its Scientific and Medical Advisory Board. Dr. Winer is a nationally recognized gynecologic oncologist and translational scientist. His expertise in women's oncology, immunotherapy, and early-phase clinical development further strengthens Ernexa's capabilities as it advances its proprietary induced mesenchymal stem cells (iMSC) platform and lead program, ERNA-101, toward key milestones, including first-in-human tria

    12/2/25 8:50:00 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of Directors

    NORWELL, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced the appointment of Scott R. Burell to its Board of Directors. Scott R. Burell is a seasoned healthcare finance executive with over two decades of experience leading public life sciences companies through complex transactions and growth phases. Currently serving as Chief Financia

    8/8/25 8:00:00 AM ET
    $DHAI
    $MBOT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales

    HINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales. A two-time U.S. Olympian with 20 years of medical device sales experience, Ms. Bailey has successfully led commercial teams to achieve sales goals.  She will report directly to Harel Gadot, the Company's CEO, President and Chairman. Ms. Bailey has held a variety of sales leadership roles. She has worked with notable companies like Boston Scientific, Abbott, Stryker and Intuitive Surgical that have equipped her with the insights necessary to drive growth and

    7/22/25 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BPTH
    $CCM
    $CNSP
    $CRBU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Caribou Biosciences Inc.

    SC 13D/A - Caribou Biosciences, Inc. (0001619856) (Subject)

    12/6/24 4:06:56 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

    SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/4/24 7:49:50 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BPTH
    $CCM
    $CNSP
    $CRBU
    Financials

    Live finance-specific insights

    View All

    Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

    Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation  Placebo-adjusted mean weight loss up to 15.3% (35.5 lbs) observed with 240 mg dose in the exploratory ACCESS II study at 36 weeks No adverse event-related treatment discontinuations observed when starting at lower 2.5 mg dose in ACCESS Open Label Extension and Body Composition Study Data comprehensively support and inform advancement to Phase 3 clinical development program in mid-2026 Company to host conference call today at 8:30 a.m. Eastern Time SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutic

    12/8/25 8:00:00 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

    SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company's once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day. To access the live webcast, please visit the Investor Relations page of the company's website at

    12/7/25 6:20:23 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

    The Company's operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1 study in platinum-resistant ovarian cancer (PROC), anticipated in H2 2026 CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its financial results for the three- and nine-month periods ended September 30, 2025, and highlighted its continued operational execution. Recent Highlights Announced a cel

    11/10/25 8:35:00 AM ET
    $ERNA
    Biotechnology: Pharmaceutical Preparations
    Health Care